Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives.
Gastrointest Cancer
; 6: 21-30, 2016.
Article
en En
| MEDLINE
| ID: mdl-28190957
ABSTRACT
Metastatic colorectal cancer (mCRC) is a prevalent disease for which combination cytotoxic chemotherapy is the mainstay of treatment. With the use of targeted therapy, including anti-angiogenic agents, there have been significant improvements in overall outcome of patients with mCRC. Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor ligand A, is approved for use in mCRC patients in both the first and second lines of therapy. With a better understanding of the disease through molecular profiling, identification of prognostic biomarkers may lead to better patient selection with improved outcomes for those affected by this disease.
Texto completo:
1
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Gastrointest Cancer
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos